stockportfolio.pro
Stocks / HSIC vs SMMT
HSIC vs SMMT: Which Stock Is the Better Buy?
Henry Schein, Inc. and Summit Therapeutics Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
SMMT is the larger company ($10.4B vs $9.8B). On the fundamentals, HSIC has the stronger return on equity (12.3% vs -163.9%). Neither shows an obvious red flag in the filings. Full numbers below — the stronger figure on each row is in green.
AI verdict — HSIC vs SMMT, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Henry Schein, Inc. (HSIC) | Summit Therapeutics Inc. (SMMT) | |
|---|---|---|
| Market cap | $9.8B | $10.4B |
| Revenue (latest FY) | $13.18B | $0 |
| Net income (latest FY) | $398.00M | $-1.08B |
| Revenue growth (5y CAGR) | 5.4% | — |
| Net margin | 3.0% | — |
| Return on equity | 12.3% | -163.9% |
| P/E ratio | 26.1 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 1 |
| Positive free cash flow | Yes | No |
Compare with another company:
See the full HSIC vs SMMT breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open HSIC's full financials → Open SMMT's full financials →More comparisons
Frequently asked questions
Which is bigger, HSIC or SMMT?
Summit Therapeutics Inc. is larger by market capitalization — $10.4B versus $9.8B.
Which grows faster, HSIC or SMMT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.